Lifecore Biomedical, Inc.
LFCR
$7.90
$0.070.89%
NASDAQ
| 09/30/2025 | 05/25/2025 | 02/23/2025 | 11/24/2024 | 08/25/2024 | |
|---|---|---|---|---|---|
| Net Income | -771.05% | 92.23% | -124.76% | 59.51% | -129.14% |
| Total Depreciation and Amortization | 3.50% | -7.80% | 1.57% | 2.56% | -1.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.93% | -65.68% | 129.62% | 16.09% | -34.41% |
| Change in Net Operating Assets | 162.18% | 57.95% | 71.94% | -216.46% | 68.02% |
| Cash from Operations | -67.05% | 345.58% | 119.64% | -850.23% | -107.38% |
| Capital Expenditure | 17.17% | 61.57% | -120.89% | 27.18% | -25.03% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 17.17% | -235.82% | 162.51% | 27.18% | -25.03% |
| Total Debt Issued | -90.59% | -- | -- | -200.00% | -98.69% |
| Total Debt Repaid | 90.43% | -1,967.05% | 45.47% | -4,803.86% | 99.84% |
| Issuance of Common Stock | -- | -- | -99.93% | 2,383,900.00% | -- |
| Repurchase of Common Stock | -576.02% | -28.57% | 65.45% | 34.63% | -1,011.32% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -118.13% | -- | -- |
| Cash from Financing | -245.27% | 94.07% | -154.19% | 1,045.01% | 278.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.86% | 170.53% | -202.62% | 233.75% | -154.59% |